Last reviewed · How we verify
Female pelvic infections — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Piperacillin And Tazobactam | Piperacillin Sodium | Pfizer | Penicillin-class antibacterial with beta-lactamase inhibitor | Bacterial cell wall; beta-lactamase enzyme | 1981-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Female pelvic infections
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Female pelvic infections:
- Female pelvic infections treatment updates — RSS
- Female pelvic infections treatment updates — Atom
- Female pelvic infections treatment updates — JSON
Cite this brief
Drug Landscape (2026). Female pelvic infections — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/female-pelvic-infections. Accessed 2026-06-10.
Related
- Female pelvic infections full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing